نتایج جستجو برای: dolutegravir
تعداد نتایج: 953 فیلتر نتایج به سال:
OBJECTIVE Among 1222 antiretroviral-naive patients who received dolutegravir (DTG) as part of first-line therapy, none has developed resistance against this compound after 48-96 weeks of follow-up. Moreover, only four occurrences of virological failure with resistance mutations have been documented in previously drug-experienced patients who received DTG as a first time integrase inhibitor as a...
BACKGROUND Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1-infected subjects with genotypic evidence of RAL resistance. METHODS Subjects received DTG 50 mg once daily (cohort I) or 50 mg twice daily (cohort...
UNLABELLED The R263K substitution in integrase has been selected in tissue culture with dolutegravir (DTG) and has been reported for several treatment-experienced individuals receiving DTG as part of salvage therapy. The R263K substitution seems to be incompatible with the presence of common resistance mutations associated with raltegravir (RAL), a different integrase strand transfer inhibitor ...
Signature HIV-1 integrase mutations associated with clinical raltegravir resistance involve 1 of 3 primary genetic pathways, Y143C/R, Q148H/K/R and N155H, the latter 2 of which confer cross-resistance to elvitegravir. In accord with clinical findings, in vitro drug resistance profiling studies with wild-type and site-directed integrase mutant viruses have shown significant fold increases in ral...
Background The dolutegravir-based antiretroviral regimen is the preferred first-line for management of people living with human immunodeficiency virus in Nepal recently. It considered safe to transition a children and adults on Nevirapine Efavirenz-based regimens.
 Objective To determine virologic response following Dolutegravir-based previously taking regimen.
 Method This retrospect...
Objectives: Following an alert on neural tube defects and dolutegravir, we sought to evaluate if the exposure integrase strand transfer inhibitors (INSTIs) at conception was associated with birth or other adverse pregnancy outcomes. Methods: In prospective national French Perinatal Cohort (EPF), studied perinatal outcomes by matching each pregnant woman exposed INSTIs a darunavir/ritonavir rece...
Objectives: Osteopenia is frequent in HIV-infected patients treated with antiretroviral therapy (ART) and has been linked to increased osteoclastogenesis. Little known about the effects of ART on osteogenesis. Design: We investigated effect human mesenchymal stem cells (hMSC) osteoblasts Darunavir Dolutegravir, most highly used as anchor drugs within a three-drug regimen, Atazanavir, which was ...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید